CAR IVT saRNA Products

Q: Is your platform capable of producing saRNA for complex, multi-cistronic CAR designs?

Absolutely. Our proprietary in vitro transcription system is engineered for high processivity and fidelity, enabling the robust synthesis of full-length, structurally intact saRNA transcripts exceeding 16 kilobases. This capacity readily supports the inclusion of multi-cistronic cassettes, such as those encoding tandem CARs, co-stimulatory ligands, or safety switches, within a single replicon vector.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Background Service Technical Information Workflow HighlightsFAQs Contact

Overcoming the challenges of transient expression, dose-limiting toxicity, and vector-related safety risks in cell therapy requires next-generation delivery platforms. Creative Biolabs' CAR IVT saRNA Products leverage proprietary, optimized self-amplifying RNA technology to enable sustained and robust CAR expression in vivo with dramatically reduced RNA input. We support partners from early research through clinical development with a complete suite of design, production, and analytical services. This integrated approach accelerates your therapeutic programs by providing a safer, more potent, and dose-sparing path to durable efficacy.

Introduction

CAR IVT saRNA leverages self-amplifying RNA technology derived from alphavirus replicons to enable sustained, high-level CAR expression directly in vivo. Unlike conventional mRNA, saRNA replicates intracellularly, providing prolonged therapeutic activity with significantly lower dosing. This approach overcomes key limitations of transient expression and systemic toxicity, offering a potent and dose-sparing platform for next-generation in vivo CAR-T cell therapies.

Fig.1 Engineering next-generation RNA vaccines: non-amplifying, self-amplifying, and circular IVT RNA. (OA Literature) Fig.1 Design strategies for self-amplifying and non-amplifying RNA vaccines.¹

CAR IVT saRNA Products at Creative Biolabs

Creative Biolabs provides end-to-end solutions for the design, synthesis, and validation of self-amplifying RNA (saRNA) encoding various CAR architectures. Our products are engineered to solve the "persistence gap" in non-viral cell engineering, ensuring that your CAR-T or CAR-NK cells maintain therapeutic pressure on tumor cells for extended durations without the need for repeated transfections.

Technical Information

Alphavirus Replicon Backbone: Our platform is built on a proprietary, non-infectious alphavirus replicon backbone that contains the viral RNA-dependent RNA polymerase complex to enable sustained intracellular self-amplification of the CAR-encoding RNA.
Optimized CAR Expression Cassette: The CAR transgene, comprising a targeting domain, hinge, transmembrane region, and tailored signaling domains, is driven by a high-activity subgenomic promoter within the replicon, ensuring robust and durable CAR surface expression.
High-Purity IVT & mRNA Engineering: CAR saRNA is produced via in vitro transcription using co‑transcriptional capping, N1-methylpseudouridine-modified nucleotides, and a defined poly(A) tail, followed by stringent HPLC-based purification to ensure translational efficiency and minimal immunogenicity.
Targeted LNP Delivery System: For in vivo application, the saRNA is formulated into ionizable lipid nanoparticles (LNPs) optimized for stability, cell tropism, and efficient endosomal escape, enabling systemic delivery and high-level transfection of target T cells.

Our Service Process

Required Starting Materials: To begin the project, please submit the digital sequence of your CAR construct in FASTA format, or alternatively, provide a plasmid map of your current vector. For custom LNP encapsulation, detailed target cell characterization data is also required to enable formulation optimization.

Key Steps:

Workflow of CAR IVT saRNA at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: Upon completion of the project, you will receive highly purified CAR saRNA, accompanied by a comprehensive Certificate of Analysis (CoA) that documents key quality attributes, as well as a detailed Functional Validation Report confirming biological activity.

Key Advantages

Tailored Process Optimization: We conduct customized upstream and downstream process development for each CAR design, optimizing for both production efficiency and product integrity.
Quality-By-Design Oversight: Our production adheres to a rigorous Quality-by-Design (QbD) framework, incorporating Process Analytical Technology (PAT) for real-time monitoring to ensure batch-to-batch consistency and high purity.
Genomic Template Assurance: The origin, quality, and stability of all master cell banks and plasmid templates are verified through formal quality assessment protocols, ensuring reliable performance during scaled-up manufacturing.

FAQs

Q1: What are the key advantages of saRNA over conventional mRNA in CAR-T therapy?

A1: saRNA incorporates an alphavirus-derived replicase complex, enabling intracellular RNA replication that extends transgene expression from days to weeks. This intrinsic amplification provides a pronounced dose-sparing benefit, typically requiring one-tenth or less of the RNA mass compared to conventional mRNA to achieve equivalent or superior levels of sustained CAR expression on T cells, thereby enhancing therapeutic potency while reducing potential toxicity.

Q2: Is your platform capable of producing saRNA for complex, multi-cistronic CAR designs?

A2: Absolutely. Our proprietary in vitro transcription system is engineered for high processivity and fidelity, enabling the robust synthesis of full-length, structurally intact saRNA transcripts exceeding 16 kilobases. This capacity readily supports the inclusion of multi-cistronic cassettes, such as those encoding tandem CARs, co-stimulatory ligands, or safety switches, within a single replicon vector.

Why Choose Us?

We provide a purpose-built QbD platform specifically engineered for next-generation CAR therapies. Unlike standard suppliers, our processes guarantee >90% full-length integrity for large, complex constructs up to 16 kb. This results in up to 10-fold higher expression per dose compared to conventional mRNA, achieved through proprietary chemistry and stringent purification that simultaneously reduce immunogenic potential and maximize intracellular durability.

Related Services

To advance next-generation cell therapy programs, we provide a fully integrated suite of in vitro transcription solutions. Our CAR IVT products series covers the complete workflow from gene cloning to final delivery, offering highly customizable and high-quality core reagents. In addition to CAR IVT saRNA products, we offer a complementary range of products including CAR IVT circRNA, CAR IVT Plasmid Products, CAR IVT mRNA Products, and CAR IVT LNP Products, delivering comprehensive support across all stages of research, development, and manufacturing.

How to contact us?

Ready to advance your CAR-T program with high-purity, dose-sparing saRNA designed for sustained in vivo expression? Our team leverages two decades of RNA and protein engineering expertise to deliver QbD solutions that accelerate development. Contact us today for a detailed project consultation and a tailored quotation.

Reference

Perenkov, Alexey D et al. "In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future." Vaccines vol. 11,10 1600. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/vaccines11101600.